A $250M target fund providing blended exposure across selective therapeutic innovation and a group of revenue-generating service and operating businesses, unified by a fund-wide AI strategy. Allocations, economics and underwriting detail are provided in the data room.
Milestone-driven equity in high-impact, longevity-focused cell and gene therapies with early signs of human efficacy, anchored by an investigational program and a staged pipeline pursuing defined proof milestones, licensing and strategic exits.
Capital is staged to verifiable proof points. The anchor is an investigational regenerative-medicine program (BioViva Neuro — investigational and not FDA approved), paired with additional innovation companies subject to diligence and defined evidence milestones. Value depends on scientific, regulatory, CMC and controlled-evidence outcomes.
Operating businesses and capabilities that combine standalone economic potential with manufacturing, patient access, evidence and operating utility that can support portfolio execution and hedge innovation risk. A fund-wide AI strategy is applied across all portfolios.
Portfolio role
GMP-grade biofabrication services intended to help control therapy costs and secure supply.
Potential economics
Third-party services, equipment, consumables, licensing and strategic asset value.
Portfolio role
Patient capture by medical concierge services directed toward an international providers network; curation of real-world outcomes data.
Potential economics
Service fees, licensing, royalties and JV economics where agreements provide.
Portfolio role
Synergistic, profitable healthcare operators — recycling capital through leveraged transactions and increasing enterprise value through operating improvements.
Potential economics
Cash flow after business needs and debt service, debt paydown, recapitalization or sale.
Portfolio support may improve execution but does not guarantee revenue, clinical success, lower cost or realization. Unless expressly identified as closed, opportunities are prospective.
Representative anchor relationships across innovation, manufacturing and patient capture. Letters of intent with BioViva and the Swiss CDMO are signed; neither transaction is closed.
Investigational hTERT + Klotho gene therapy for neurodegeneration. Controlled human evaluation is a key value milestone. Investigational and not FDA approved.
GMP-grade, Swiss-based CDMO with expertise in manufacturing exosomes and cell and gene therapies.
Medical concierge with an international network of top providers specialized in regenerative medicine and science-based longevity.
BioViva CEO Liz Parrish is an Aether general partner, creating a related-party conflict that is managed and disclosed. Company names and relationships are subject to diligence and definitive documents and may change.
Company value, Aether's economic interest, realized fund cash and LP distributions are distinct steps and should not be treated as interchangeable.
Illustrative only. Realizations and distributions are not assured. Repaid or recycled principal is not additional profit. Modeled returns and fund terms are provided in the data room under NDA.
Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Company names, allocations, valuations, timelines and economics are forward-looking, subject to diligence and definitive documents, and may change. Investigational programs are not FDA approved. Investments are illiquid and may result in total loss of capital.